Par Drugs And Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Par Drugs and Chemicals Limited submitted its unaudited standalone financial results for the quarter ended June 30, 2025. Revenue from operations rose to ₹2,604.64 lakhs from ₹2,260.56 lakhs in Q1 FY25, a growth of about 15% year-on-year. Profit after tax jumped roughly 31% YoY to ₹332.81 lakhs, with EPS improving to ₹2.70 from ₹2.06. Profit before tax came in at ₹447.78 lakhs, up 32% YoY, supported by higher other income of ₹183.67 lakhs. The statutory auditor (Sarupria Somani & Associates) issued a clean limited review report with no qualifications. The board also approved renewal of a ₹161 lakh banking facility with Kotak Mahindra Bank with no change in limits.
Strong ~31% YoY PAT growth and margin expansion indicate healthy operational performance, which is a positive signal for shareholders. The clean auditor report and routine banking facility renewal carry no negative concerns, but the modest revenue growth of ~15% (below 20%) tempers the upside narrative.